Non-Small Cell Lung Cancer
Even after an adverse event due to treatment with a checkpoint inhibitor, some patients may benefit from re-treatment with drugs from this class.
The heterogeneity of resistance may make it difficult for drug developers to create combination therapies that prevent eventual resistance to osimertinib.
Small cell lung cancer, a highly aggressive disease, is diagnosed in 34,000 patients and accounts for nearly 18% of all lung cancer cases in the United States every year.
Previous studies have demonstrated that osimertinib may have the potential to improve outcomes among patients with central nervous system metastases.
Routine, Targeted Next-Generation Sequencing Is Feasible for Patients with Non-Small Cell Lung CancerAugust 01, 2018
Researchers retrospectively examined 2448 cases of NSCLC submitted to a single diagnostics lab over 3 years.
Recent findings identified interactions between the EGFR and estrogen receptor signaling pathways, which could potentially modify outcomes in non-small cell lung cancer.
The researchers argue that upfront next-generation sequencing should be the new standard of care.
"BRAF-mutated NSCLC represents an emerging targetable entity among the scenario of oncogene-driven NSCLC."
EGFR tyrosine kinase inhibitor monotherapy has improved progression-free survival (PFS) but not overall survival (OS) compared with chemotherapy in non-small cell lung cancer.
Recent studies have explored the potential of combination therapy with EGFR-TKIs and VEGF-inhibitors for patients with EGFR-positive non-small cell lung cancer.
Enriqueta Felip, MD, PhD, discusses her findings at the ASCO 2018 meeting in Chicago.
Some figures show that incidence of brain metastasis is approximately 30% 2 years after being diagnosed with non-small cell lung cancer.
The phase 3 study found the combination effective, regardless of tumor proportion score.
PD-1/PD-L1 ICI can offer remarkable benefits as first- and second-line treatments for NSCLC, but 80% of patients do not respond to immunotherapy, and many of those who do respond eventually see their cancers acquire drug resistance.
Researchers accessed the French National Hospital registry and obtained the records of 64,950 patients who died of metastatic NSCLC between 2010 and 2013.
Non-small cell lung cancer largely remains incurable and is associated with high symptom burden and reduced quality of life.
At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.
Previous studies have demonstrated that crizotinib — a tyrosine kinase inhibitor (TKI) of ALK, MET, and ROS1 kinases — has markedly increased antitumor activity among patients with ROS1-positive NSCLC.
Few long-term data of the drug's safety and efficacy in patients with NSCLC were previously available.
Cancer-associated weight loss is linked to worse survival outcomes among patients with cancer.
The safety profile of each agent was consistent with those previously reported.
Researchers evaluated whether different complex mutations lead to different clinical outcomes among patients treated with EGFR-TKIs.
Efforts are underway to develop predictive molecular biomarkers that can improve patient selection for ICIs.
Previous studies demonstrated that fruquintinib may have clinical value for patients who fail at least 2 prior lines of therapy.
The FDA based its approval on positive findings from the phase 3 PACIFIC study.
Researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with NSCLC or urothelial cancer.
Living in a lower-education area and being African American were associated with not receiving any cancer-directed care.
PSPT significantly reduced radiation exposure to the heart, but no differences were observed between PSPT and IMRT for the lung or esophagus.
Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.
One trial is evaluating whether an HDAC inhibitor, mocetinostat, in combination with a demethylating drug, guadecitabine, can boost responses to pembrolizumab in patients with advanced NSCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Aspirin and Colorectal Cancer
- Study Reveals Scope of Genomic Variation Within Cancer Cell Lines
- IL-23 Drives Castration-Resistant Prostate Cancer
- Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer
- Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer
- FDA Grants Accelerated Approval to Nivolumab for Small Cell Lung Cancer
- Accelerated Intensity-Modulated Radiotherapy May Improve Outcomes in Localized Lung Cancer
- FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma
- COPD May Not Affect Survival in Patients With Small Cell Lung Cancer
- Prescription Drug Coverage in Medicare Part D Is Tied to a Survival Advantage in Myeloma